17:07 EDT Monday, May 05, 2008

VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 5, 2008) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") announces that it has granted incentive stock options to a consultant to purchase an aggregate of 250,000 common shares at an exercise price of $0.80 and a term of three years, expiring on May 5, 2011. The options and shares issuable upon exercise, if any, will be subject to a four-month hold period from the date of grant in accordance with TSX Venture Exchange policy. The grant was pursuant to the Company's Rolling Stock Option Plan, which was re-affirmed by the shareholders of the Company on December 14, 2007 and subsequently accepted by the Exchange. The total number of options outstanding after this grant will be 4,800,000.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T36(R) technology. The company trades on the TSX Venture Exchange under the symbol APH.

Terrance G. Owen, Ph.D., MBA, President, CEO and Director

ALDA Pharmaceuticals Corp.

FOR FURTHER INFORMATION PLEASE CONTACT:

ALDA Pharmaceuticals Corp. Peter Chen Distribution & Sales Contact (604) 521-8300 Ext. 3 (604) 521-8322 (FAX) Email: peter_chen@aldacor